<DOC>
	<DOCNO>NCT01314209</DOCNO>
	<brief_summary>The purpose study determine dexmedetomidine pharmacokinetics continuous renal replacement therapy critically ill patient .</brief_summary>
	<brief_title>Dexmedetomidine Pharmacokinetics During Continuous Renal Replacement Therapy ( CRRT )</brief_title>
	<detailed_description>Dexmedetomidine selective alpha-2-adrenergic agonist sedative property indicate sedation patient intensive care set . ICU patient acute kidney injury require renal replacement therapy frequently change volume status cause alteration drug pharmacokinetics . Although dexmedetomidine pharmacokinetics study earlier ICU patient , information pharmacokinetics critically ill patient need continuous renal replacement therapy .</detailed_description>
	<mesh_term>Acute Kidney Injury</mesh_term>
	<mesh_term>Dexmedetomidine</mesh_term>
	<criteria>Age â‰¥ 18 Clinical need sedation Acute kidney injury require renal replacement therapy ( accord ICUs standard operating procedure ) Severe bradycardia ( HR &lt; 50/min ) AV conduction block IIIII ( unless pacemaker instal ) Severe hepatic impairment ( bilirubin &gt; 101 umol/l ) Pregnancy lactation Age &lt; 18</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>dexmedetomidine</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>critical illness</keyword>
	<keyword>continuous renal replacement therapy</keyword>
</DOC>